Inhibikase Therapeutics Stock Price History
| IKT Stock | USD 2.30 0.04 1.71% |
Below is the normalized historical share price chart for Inhibikase Therapeutics extending back to December 23, 2020. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Inhibikase Therapeutics stands at 2.30, as last reported on the 1st of March, with the highest price reaching 2.54 and the lowest price hitting 2.23 during the day.
If you're considering investing in Inhibikase Stock, it is important to understand the factors that can impact its price. Currently, Inhibikase Therapeutics is very risky. Inhibikase Therapeutics holds Efficiency (Sharpe) Ratio of close to zero, which attests that the entity had a close to zero % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Inhibikase Therapeutics, which you can use to evaluate the volatility of the firm. Please check out Inhibikase Therapeutics' Market Risk Adjusted Performance of (0.30), risk adjusted performance of 0.0581, and Downside Deviation of 8.62 to validate if the risk estimate we provide is consistent with the expected return of 0.0134%.
At this time, Inhibikase Therapeutics' Common Stock is comparatively stable compared to the past year. Total Stockholder Equity is likely to gain to about 13.7 M in 2025, whereas Other Stockholder Equity is likely to drop slightly above 46.4 M in 2025. . At this time, Inhibikase Therapeutics' Price Book Value Ratio is comparatively stable compared to the past year. Price To Book Ratio is likely to gain to 0.58 in 2025, whereas Price Earnings To Growth Ratio is likely to drop 0.02 in 2025. Inhibikase Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 23rd of December 2020 | 200 Day MA 2.0071 | 50 Day MA 2.8064 | Beta 1.065 |
Inhibikase |
Sharpe Ratio = 0.0017
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IKT |
Estimated Market Risk
| 7.81 actual daily | 69 69% of assets are less volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Inhibikase Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Inhibikase Therapeutics by adding Inhibikase Therapeutics to a well-diversified portfolio.
Price Book 26.456 | Enterprise Value Ebitda 0.3409 | Price Sales 1000 K | Shares Float 16.7 M | Wall Street Target Price 8 |
Inhibikase Therapeutics Stock Price History Chart
There are several ways to analyze Inhibikase Stock price data. The simplest method is using a basic Inhibikase candlestick price chart, which shows Inhibikase Therapeutics price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | December 17, 2024 | 3.97 |
| Lowest Price | January 30, 2025 | 1.92 |
Inhibikase Therapeutics March 1, 2025 Stock Price Synopsis
Various analyses of Inhibikase Therapeutics' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Inhibikase Stock. It can be used to describe the percentage change in the price of Inhibikase Therapeutics from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Inhibikase Stock.| Inhibikase Therapeutics Price Rate Of Daily Change | 0.98 | |
| Inhibikase Therapeutics Accumulation Distribution | 39,835 | |
| Inhibikase Therapeutics Price Action Indicator | (0.11) | |
| Inhibikase Therapeutics Price Daily Balance Of Power | (0.13) |
Inhibikase Therapeutics March 1, 2025 Stock Price Analysis
Inhibikase Stock Price History Data
The price series of Inhibikase Therapeutics for the period between Sun, Dec 1, 2024 and Sat, Mar 1, 2025 has a statistical range of 2.05 with a coefficient of variation of 15.39. Under current investment horizon, the daily prices are spread out with arithmetic mean of 2.79. The median price for the last 90 days is 2.8. The company completed 1:6 stock split on 30th of June 2023.| Open | High | Low | Close | Volume | ||
| 02/28/2025 | 2.32 | 2.54 | 2.23 | 2.30 | 326,393 | |
| 02/27/2025 | 2.41 | 2.43 | 2.31 | 2.34 | 92,049 | |
| 02/26/2025 | 2.23 | 2.46 | 2.23 | 2.38 | 120,350 | |
| 02/25/2025 | 2.45 | 2.50 | 2.17 | 2.24 | 194,183 | |
| 02/24/2025 | 2.82 | 2.89 | 2.38 | 2.48 | 247,727 | |
| 02/21/2025 | 3.32 | 3.32 | 2.93 | 2.97 | 266,630 | |
| 02/20/2025 | 3.08 | 3.32 | 2.99 | 3.26 | 283,467 | |
| 02/19/2025 | 2.61 | 3.10 | 2.52 | 3.08 | 261,011 | |
| 02/18/2025 | 2.28 | 2.64 | 2.28 | 2.60 | 228,028 | |
| 02/14/2025 | 2.21 | 2.38 | 2.21 | 2.35 | 122,528 | |
| 02/13/2025 | 2.29 | 2.33 | 2.20 | 2.23 | 91,162 | |
| 02/12/2025 | 2.25 | 2.39 | 2.25 | 2.26 | 139,272 | |
| 02/11/2025 | 2.40 | 2.45 | 2.34 | 2.34 | 156,200 | |
| 02/10/2025 | 2.25 | 2.51 | 2.25 | 2.44 | 256,730 | |
| 02/07/2025 | 2.42 | 2.53 | 2.31 | 2.35 | 154,401 | |
| 02/06/2025 | 2.35 | 2.53 | 2.29 | 2.43 | 239,541 | |
| 02/05/2025 | 2.22 | 2.34 | 2.19 | 2.33 | 156,996 | |
| 02/04/2025 | 2.16 | 2.28 | 2.07 | 2.27 | 159,356 | |
| 02/03/2025 | 2.20 | 2.37 | 2.03 | 2.16 | 227,847 | |
| 01/31/2025 | 1.90 | 2.29 | 1.90 | 2.27 | 442,326 | |
| 01/30/2025 | 2.17 | 2.59 | 1.91 | 1.92 | 982,581 | |
| 01/29/2025 | 2.75 | 2.85 | 2.71 | 2.80 | 430,040 | |
| 01/28/2025 | 2.69 | 2.78 | 2.66 | 2.76 | 81,947 | |
| 01/27/2025 | 2.82 | 2.85 | 2.66 | 2.74 | 84,282 | |
| 01/24/2025 | 2.86 | 2.90 | 2.74 | 2.81 | 80,767 | |
| 01/23/2025 | 2.79 | 2.96 | 2.73 | 2.83 | 119,298 | |
| 01/22/2025 | 2.80 | 2.84 | 2.71 | 2.80 | 80,658 | |
| 01/21/2025 | 2.76 | 2.89 | 2.62 | 2.81 | 126,380 | |
| 01/17/2025 | 2.77 | 2.85 | 2.67 | 2.72 | 39,867 | |
| 01/16/2025 | 2.76 | 2.90 | 2.55 | 2.76 | 92,417 | |
| 01/15/2025 | 2.70 | 2.84 | 2.68 | 2.73 | 83,398 | |
| 01/14/2025 | 2.75 | 2.98 | 2.59 | 2.66 | 86,646 | |
| 01/13/2025 | 2.85 | 3.03 | 2.66 | 2.66 | 147,978 | |
| 01/10/2025 | 3.00 | 3.10 | 2.86 | 2.95 | 178,433 | |
| 01/08/2025 | 3.25 | 3.35 | 3.06 | 3.10 | 102,078 | |
| 01/07/2025 | 3.11 | 3.34 | 3.11 | 3.21 | 190,718 | |
| 01/06/2025 | 3.25 | 3.47 | 3.15 | 3.16 | 301,905 | |
| 01/03/2025 | 3.36 | 3.36 | 3.11 | 3.32 | 188,735 | |
| 01/02/2025 | 3.49 | 3.49 | 3.14 | 3.29 | 82,807 | |
| 12/31/2024 | 3.36 | 3.49 | 3.04 | 3.25 | 200,894 | |
| 12/30/2024 | 3.05 | 3.24 | 2.96 | 3.24 | 132,322 | |
| 12/27/2024 | 3.04 | 3.12 | 2.91 | 3.05 | 59,475 | |
| 12/26/2024 | 2.95 | 3.10 | 2.90 | 3.06 | 101,900 | |
| 12/24/2024 | 2.92 | 3.05 | 2.92 | 2.96 | 66,079 | |
| 12/23/2024 | 3.23 | 3.23 | 2.90 | 2.96 | 176,073 | |
| 12/20/2024 | 3.13 | 3.50 | 3.07 | 3.20 | 1,800,283 | |
| 12/19/2024 | 3.64 | 3.88 | 3.11 | 3.16 | 837,158 | |
| 12/18/2024 | 4.04 | 4.20 | 3.65 | 3.65 | 892,725 | |
| 12/17/2024 | 3.58 | 4.14 | 3.55 | 3.97 | 931,036 | |
| 12/16/2024 | 3.55 | 3.94 | 3.55 | 3.57 | 1,016,808 | |
| 12/13/2024 | 3.18 | 3.50 | 3.17 | 3.44 | 349,818 | |
| 12/12/2024 | 3.21 | 3.50 | 3.12 | 3.24 | 246,358 | |
| 12/11/2024 | 3.15 | 3.55 | 3.15 | 3.20 | 412,340 | |
| 12/10/2024 | 3.22 | 3.60 | 3.17 | 3.20 | 288,407 | |
| 12/09/2024 | 3.54 | 3.61 | 3.02 | 3.21 | 523,569 | |
| 12/06/2024 | 2.68 | 3.33 | 2.68 | 3.28 | 408,733 | |
| 12/05/2024 | 2.71 | 2.81 | 2.57 | 2.73 | 141,942 | |
| 12/04/2024 | 2.77 | 2.85 | 2.63 | 2.74 | 140,618 | |
| 12/03/2024 | 2.70 | 2.90 | 2.66 | 2.80 | 179,125 | |
| 12/02/2024 | 2.99 | 3.17 | 2.70 | 2.76 | 270,934 | |
| 11/29/2024 | 2.76 | 2.98 | 2.76 | 2.92 | 179,157 |
About Inhibikase Therapeutics Stock history
Inhibikase Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Inhibikase is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Inhibikase Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Inhibikase Therapeutics stock prices may prove useful in developing a viable investing in Inhibikase Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 6.1 M | 3.2 M | |
| Net Loss | -13.3 M | -12.6 M |
Inhibikase Therapeutics Stock Technical Analysis
Inhibikase Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Cryptocurrency Center Now
Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
| All Next | Launch Module |
Inhibikase Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Inhibikase Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Inhibikase Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Inhibikase to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0581 | |||
| Jensen Alpha | 0.482 | |||
| Total Risk Alpha | 0.7698 | |||
| Sortino Ratio | 0.0631 | |||
| Treynor Ratio | (0.31) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.